Skip to main content
SpringerLink
Log in
Book cover

Uveal Melanoma pp 135–149Cite as

Nanoparticles for the Treatment of Uveal Melanoma

  • Chapter
  • First Online:

  • 410 Accesses

Abstract

Nanoparticles consisting of viral-like particles (VLPs) derived from human papilloma virus capsid proteins L1 and L2 conjugated to a phthalocyanine-based photosensitizer, IRDye®700DX, have been developed as AU-011, a novel viral-like particle bioconjugate (VPB). AU-011 is currently under investigation for the treatment of choroidal melanoma. The VLP provides targeting to tumor cells by binding to specifically modified heparan sulfate proteoglycans found on the surface of malignant cells. Further specificity is provided by local light activation of the dye over the tumor. Preclinical studies in rabbit models have shown tumor necrosis after intravitreal as well as suprachoroidal administration of AU-011. Early-stage clinical studies to date have shown an acceptable safety profile with promising rates of visual preservation and tumor control.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. National Nanotechnology Initiative. What It Is and How It Works [Internet]. [cited Nov 2020]. Available from: https://www.nano.gov/nanotech-101/what.

  2. National Cancer Institute. Cancer and Nanotechnology [Internet]. [cited Nov 2020]. Available from: https://www.cancer.gov/nano/cancer-nanotechnology.

  3. IMLYGIC [package insert]. Thousand Oaks, California: Amgen; 2015.

    Google Scholar 

  4. Andtbacka RH, Collichio FA, Amatruda T, Senzer NN, Chesney J, Delman KA, et al. OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J Clin Oncol. 2013;31(suppl):Abstr LBA9008.

    Article  Google Scholar 

  5. Alemany R. Viruses in cancer treatment. Clin Trans Oncol. 2013;15:182–8.

    Article  CAS  Google Scholar 

  6. Vacchelli E, Eggermon A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, et al. Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology. 2013;2:e24612.

    Article  Google Scholar 

  7. Steinmetz NF. Viral nanoparticles as platforms for next-generation therapeutics and imaging devices. Nanomedicine. 2010;6(5):634–41.

    Article  CAS  Google Scholar 

  8. Kines RC, Varsavsky I, Choudhary S, Bhattacharya D, Spring S, McLaughlin R, Kang SJ, Grossniklaus HE, Demetrios V, Monks S, MacDougall JR, de los Pinos E, Schiller J. An infrared dye-conjugated virus-like particle for the treatment of primary uveal melanoma. Mol Cancer Ther. 2018;17:565–74.

    Article  CAS  Google Scholar 

  9. Kines RC, Cerio RJ, Roberts JN, Thompson CD, de Los Pinos E, Lowy DR, Schiller JT. Human papillomavirus capsids preferentially bind and infect tumor cells. Int J Cancer. 2016;138:901–11.

    Article  CAS  Google Scholar 

  10. Johnson K, Kines R, Roberts J, Lowy D, Schiller J, Day P. Role of heparan sulfate in attachment to and injection of the female genital tract by human papillomavirus. J Virol. 2009;83:2067–74.

    Article  CAS  Google Scholar 

  11. Kines RC, Thompson CD, Lowy DR, Schiller JT, Day PM. The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc Natl Acad Sci U S A. 2009;106(48):20458–63.

    Article  CAS  Google Scholar 

  12. Blackhall FH, Merry CL, Davies EJ, Jayson GC. Heparan sulfate proteoglycans and cancer. Br J Cancer. 2001;785:1094–8.

    Article  Google Scholar 

  13. Perrimon N, Bernfield M. Specificities of heparan sulfate proteoglycans in developmental processes. Nature. 2000;404:725–8.

    Article  CAS  Google Scholar 

  14. Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK, Yayon A, et al. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell. 2000;6:743–50.

    Article  CAS  Google Scholar 

  15. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer. 2005;5:526–42.

    Article  CAS  Google Scholar 

  16. Hung C-F, Chiang AJ, Tsai H-H, Pomper MG, Kang TH, Roden RR, Wu T-C. Ovarian Cancer Gene Therapy Using HPV-16 Pseudovirion Carrying the HSV-tk Gene. PLoS One. 2012;7(7):e40983.

    Article  CAS  Google Scholar 

  17. Hojeij R, Domingos-Pereira S, Nkosi M, Gharbi D, Derré L, Schiller JT, Jichlinski P, Nardelli-Haefliger D. Immunogenic Human Papillomavirus Pseudovirus-Mediated Suicide-Gene Therapy for Bladder Cancer. Int J Mol Sci. 2016 Jul;17(7):1125.

    Article  Google Scholar 

  18. Mitsunaga M, Nakajima T, Sano K, Kramer-Marek G, Choyke P, Kobayashi H. Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy. BMC Cancer. 2012;12:345.

    Article  CAS  Google Scholar 

  19. Grimm J, Scheinberg D. Will nanotechnology influence targeted cancer therapy? Semin. Radiat Oncol. 2011;21:80–7.

    Article  Google Scholar 

  20. Savinainen A, Grossniklaus H, Kang S, Rasmussen C, Bentley E, Krakova Y, Struble CB, Rich C. Ocular distribution and efficacy after suprachoroidal injection of AU-011 for treatment of ocular melanoma. Invest Ophthalmol Vis Sci. 2020;61(7):3615.

    Google Scholar 

  21. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT03052127, Study in Subjects with Small Primary Choroidal Melanoma; 2017 Feb 14 [cited 2020 Nov]; [about 8 screens]. Available from: https://clinicaltrials.gov/ct2/show/NCT03052127.

  22. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT04417530, Phase 2 trial to evaluate safety and efficacy of AU-011 via suprachoroidal administration in subjects with primary indeterminate lesions and small choroidal melanoma; 2020 June 4 [cited 2020 Nov]; [about 6 screens]. Available from: https://clinicaltrials.gov/ct2/show/NCT04417530.

  23. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT03941379, a registry of patients with primary Choroidal Melanoma (CM) or Indeterminate Lesions (ILs); 2019 May 7 [cited 2020 Nov]; [about 6 screens]. Available from: https://clinicaltrials.gov/ct2/show/NCT03941379.

  24. Shields CL, et al. AU-011, a targeted therapy for primary treatment of Choroidal Melanoma (CM) via Intravitreal (IVT) and Suprachoroidal (SC) Administration. Session: RET10V. Late Breaking Developments, Part I. Topic: Retina, Vitreous. AAO 2020 Nov 13–15, Virtual Meeting.

    Google Scholar 

  25. Kim IK, et al. Update from an ongoing phase 1b/2 open-label trial with IVT AU-011 for CM and further development plan. Session: PA034, Paper. Topic: Ocular Pathology, Oncology. AAO 2020 Nov 13–15, Virtual Meeting.

    Google Scholar 

  26. COMS. Collaborative Ocular Melanoma Study Group Report No. 16. Collaborative Ocular Melanoma Study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years. Ophthalmology. 2001c;2001(108):348–66.

    Google Scholar 

  27. Shields CL, Sioufi K, Srinivasan A, Di Nicola M, Masoomian B, Barna LE, Bekerman VP, Say EA, Mashayekhi A, Emrich J, Komarnicky L, Shields JA. Visual outcome and millimeter incremental risk of metastasis in 1780 patients with small choroidal melanoma managed by plaque radiotherapy. JAMA Ophthalmol. 2018;136(12):1325–33.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Aura Biosciences, Inc, Cambridge, MA, USA

    Abhijit Narvekar, Cadmus Rich & Anneli Savinainen

  2. Ocular Melanoma Center, Retina Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA

    Ivana K. Kim

Authors
  1. Abhijit Narvekar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cadmus Rich
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anneli Savinainen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ivana K. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ivana K. Kim .

Editor information

Editors and Affiliations

  1. Cancer Center, Houston Methodist Hospital, Houston, TX, USA

    Eric H. Bernicker

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Narvekar, A., Rich, C., Savinainen, A., Kim, I.K. (2021). Nanoparticles for the Treatment of Uveal Melanoma. In: Bernicker, E.H. (eds) Uveal Melanoma. Springer, Cham. https://doi.org/10.1007/978-3-030-78117-0_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-78117-0_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-78116-3

  • Online ISBN: 978-3-030-78117-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation